S G Jadhav

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Parin Sangoi

Deepti Vishwanathan

Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College

Nilesh Wasekar

Indian Numismatic, Historical and Cultural Research Foundation

Rajesh Patil

Gandhi Medical College

A. Kwatra

Sardar Patel Medical College

V. Bangal

Pravara Institute of Medical Sciences

Ravindra Zore

IP Anand

Gujarat Ayurved University

Neetu Agarwal

GLA University

KS Patel

Gujarat Ayurved University

Cooperative Institutions

Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals

King Edward Memorial Hospital and Seth G.S. Medical College

Marymount University

Government Medical College

Pravara Institute of Medical Sciences

Gujarat Ayurved University

Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College

Sardar Patel Medical College

Hindu Rao Hospital

Government Dental College & Research Institute

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Clinical presentation and diagnosis of mucopolysaccharidosis type 2 (Hunter syndrome).

PubMed (2013)

Rajesh Patil Nilesh Wasekar S G Jadhav Ravindra Zore Parin Sangoi

Introduction : We present a very rare case of mucopolysaccharidosis type II (Hunter syndrome). which presented as short stature, coarse facies, mild mental retardation with no corneal clouding and repeated upper respiratory tract infections. the purpose of presenting this case is to highlight the clinical manifestations specific to mucopolysaccharidosis type II (Hunter syndrome). Case Presentation : a 20-years-old Indian male presented with short stature, coarse facial features, protruded abdomen with umbilical hernia with history of bilateral ear discharge. there was mild mental retardation and body joints were in flexed posture. Based on clinical presentation possibility of mucopolysaccharidosis is kept and based on 24 hr total urinary excretion of glycosaminoglycans (21.9 mg/mmolcreat; normal<8 mg/mmolcreat.), genotype analysis (revealing mutation p.asp198ala in exon 5 of Iduronidase 2 sulfatase gene), we diagnosed type 2 mucopolysaccharidosis (Hunter syndrome). We refered him to higher centre for enzyme replacement therapy. Conclusion : Based on clinical findings and radiological features it is possible to diagnose a case of mucopolysaccharidosis.24 hrs urinary glycosaminoglycans estimation and genetic studies confirms the diagnosis and its type, which will help in offering enzyme replacement therapy to the given individual.

Mucopolysaccharidosis

Presentation (obstetrics)

Mucopolysaccharidosis type I

Mucopolysaccharidosis I

Mucopolysaccharidosis type II

Source

Cite

Citations (2)

Isolated Subclavian Artery Thrombosis.

PubMed (2015)

S G Jadhav Neetu Agarwal Nitin Sarate Avinash Gutte Sagar Walinjkar

We presume this case to highlight the importance of underestimated percutaneous angioplasty with stent in isolated subclavian artery thrombosis.

Source

Cite

Citations (0)

LOW DOSE MAGNESIUM SULPHATE REGIME FOR ECLAMPSIA

Pravara medical review (2009)

V. Bangal A. Kwatra Sanjay Raghav S G Jadhav

Pre- eclampsia is one of the commonest medical complications seen during pregnancy. It contributes significantly to maternal and perinatal morbidity and mortality. Dr.J.A.Pritchard in 1955, introduced magnesium sulphate for control of convulsions in eclampsia and is used worldwide. Considering the low body mass index of indian women, a low dose magnesium sulphate regime has been introduced by some authors. Present study was carried out at tertiary care centre in rural area. Fifty cases of eclampsia were randomly selected to find out the efficacy of low dose magnesium sulphate regime to control eclamptic convulsions. Maternal and perinatal outcome and magnesium toxicity were analyzed. It was observed that 86% cases responded to initial intravenous dose of 4 grams of 20% magnesium sulphate . Eight percent cases, who got recurrence of convulsion, were controlled by additional 2 grams of 20% magnesium sulphate. Six percent cases required shifting to standard Pritchard regime, as they did not respond to low dose magnesium sulphate regime. The average total dose of magnesium sulphate required for control of convulsions was 20 grams ie. 54.4% less than that of standard Pritchard regime. The maternal and perinatal morbidity and mortality in the present study were comparable to those of standard Pritchard regime. The study did not find a single case of magnesium related toxicity with low dose magnesium sulphate regime. Low dose magnesium sulphate regime was found to be safe and effective in eclampsia.

Convulsion

Magnesium deficiency (plants)

Source

Cite

Citations (8)

Chorea as a rare manifestation of hyperglycaemia.

PubMed (2013)

Rajesh Patil Parin Sangoi Nilesh Wasekar Deepti Vishwanathan S G Jadhav

We present a case of chorea presenting as a clinical manifestation of hyperglycaemia.The purpose of presenting this case is to highlight the fact that movement disorder may be the clinical presentation of hyperglycaemia and it reverts on treatment of hyperglycaemia.A 66-year-old female known case of type 2 diabetes mellitus and on oral hypoglycaemic drugs presented with abnormal and involuntary movements of the whole body and face since 7 days and high plasma glucose (446 mg/dl) and without ketosis. On controlling the blood sugar, there has been significant decrease in choreiform movements within 48 hrs and complete resolution of involuntary movements found at discharge at 1 week.Movement disorder like chorea may be the clinical presentation of the hyperglycaemia which could completely recover on rapid detection and correction of hyperglycaemia.

Choreiform movement

Presentation (obstetrics)

Blood sugar

Ketosis

Movement Disorders

Source

Cite

Citations (1)

Effect of Triphaladi Avaleha as an adjuvant therapy in the management of Thalassemia

AYU (An International Quarterly Journal of Research in Ayurveda) (2010)

KS Patel S G Jadhav IP Anand

Thalassemia is the most common inherited single-gene (autosomal recessive) disorder in the world. Scientists worldwide predict that thalassemia will become a considerable health issue in the next century. It is a new disease entity for Ayurvedic medicine, and hence, it is called Anukta Vyadhi in Ayurveda; but we can understand it by careful scrutiny of the clinical presentation and the investigation results described in the available literature. Modern medical management is aimed at maintaining the hemoglobin level at 10 - 12 g/dl. A post-transfusion hemoglobin level of 9.5 g/dl is said to be sufficient to maintain active life. Thus, blood transfusion therapy is the only treatment, but it can result in hemosiderosis (iron overload), a complication with a fatal outcome. The transfusional iron overload is compounded by increased intestinal absorption of iron. The most important factors associated with survival, and also those deciding the outcome of bone marrow transplant (the only curative therapy) are, age at which chelation therapy is introduced and the success with which serum ferritin is maintained below 2500 ng/ml. Iron chelators used in modern medicine to achieve this goal are expensive and associated with side effects, and hence, associated with poor adherence to the treatment. The present study is an endeavor to explore the efficacy of Triphaladi Avaleha as an iron chelator in the management of thalassemia, in comparison to a control group managed by routine modern therapy.

Hemosiderosis

Chelation Therapy

Transfusion Therapy

Ineffective erythropoiesis

Adjuvant Therapy

10.4103/0974-8520.82026

Cite

Citations (1)